An introduction to the Marburg virus vaccine consortium, MARVAC. [PDF]
PLoS Pathogens, 2022 The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious ...
Robert W Cross +44 more
doaj +6 more sources
Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus [PDF]
Emerging Microbes and Infections, 2023 Infection with Marburg virus (MARV), the causative agent of Marburg virus disease (MVD), results in haemorrhagic disease and high case fatality rates (>40%) in humans. Despite its public health relevance, there are no licensed vaccines or therapeutics to
Cecilia A. Prator +8 more
doaj +5 more sources
Pathogenicity and virulence of Marburg virus
Virulence, 2022 Marburg virus (MARV) has been a major concern since 1967, with two major outbreaks occurring in 1998 and 2004. Infection from MARV results in severe hemorrhagic fever, causing organ dysfunction and death.
Mehedy Hasan Abir +13 more
doaj +5 more sources
Nature Communications, 2017 Bats are natural hosts for Marburg virus (MARV), but the mechanism of bat-to-bat transmission is unclear. Here, Schuhet al. monitor MARV infection in a cohort of 38 bats over nine months, find ‘supershedders’ and show that MARV can horizontally transmit ...
Amy J. Schuh +9 more
doaj +3 more sources
Emerging Microbes and Infections, 2023 Marburg virus disease (MVD) is a lethal viral haemorrhagic fever caused by Marburg virus (MARV) with a case fatality rate as high as 88%. There is currently no vaccine or antiviral therapy approved for MVD.
Jinhao Bi +12 more
doaj +4 more sources
Computational Modeling and Evaluation of Potential mRNA and Peptide-Based Vaccine against Marburg Virus (MARV) to Provide Immune Protection against Hemorrhagic Fever. [PDF]
Biomed Res Int, 2023 A hemorrhagic fever caused by the Marburg virus (MARV) belongs to the Filoviridae family and has been classified as a risk group 4 pathogen. To this day, there are no approved effective vaccinations or medications available to prevent or treat MARV infections.
Albaqami FF +6 more
europepmc +3 more sources
Filovirus Surveillance in Communities Bordering Equatorial Guinea, Marburg Outbreak, Cameroon, 2023 [PDF]
Emerging Infectious DiseasesAfter the 2023 Equatorial Guinea Marburg virus (MARV) outbreak, surveillance of 181 persons in southern Cameroon detected MARV antibodies in 3 persons and Ebola virus antibodies in 7.
Jill-Léa Ramassamy +17 more
doaj +2 more sources
Development of an Immunochromatography Assay to Detect Marburg Virus and Ravn Virus
Viruses, 2023 The recent outbreaks of Marburg virus disease (MVD) in Guinea, Ghana, Equatorial Guinea, and Tanzania, none of which had reported previous outbreaks, imply increasing risks of spillover of the causative viruses, Marburg virus (MARV) and Ravn virus (RAVV),
Katendi Changula +13 more
doaj +3 more sources
Genomic Insights into Marburg Virus Strains from 2023 and 2025 Outbreaks in Kagera, Tanzania [PDF]
Emerging Infectious DiseasesMarburg virus (MARV) is the primary cause of Marburg virus disease (MVD), a severe hemorrhagic fever with a high case-fatality rate. The first reported MVD outbreak in Tanzania occurred in 2023, followed by a second outbreak in 2025, both within the ...
Lawrence A. Mapunda +45 more
doaj +2 more sources
Discovery of potent cross-neutralizing antibodies against Marburg and Ravn viruses with therapeutic potential [PDF]
npj VirusesMarburg virus (MARV) and Ravn virus (RAVV) are highly pathogenic filoviruses that cause Marburg virus disease (MVD), for which no approved treatment currently exists.
Takeshi Saito +13 more
doaj +2 more sources